Source comparison
MK-677 vs Actual Growth Hormone: Critical Distinctions
Researchers frequently conflate growth hormone secretagogues with exogenous GH itself. The mechanisms produce overlapping outcomes but through fundamentally different pathways. Recombinant human growth hormone (rhGH) delivers supra-physiological hormone concen
This comparison does not assign a generated winner or score.
- Researchers frequently conflate growth hormone secretagogues with exogenous GH itself. The mechanisms produce overlapping outcomes but through fundamentally different pathways. Recombinant human growth hormone (rhGH) delivers supra-physiological hormone concentrations that suppress natural GH production via hypothalamic-pituitary negative feedback. Ibutamoren preserves endogenous GH pulsatility while amplifying peak levels, maintaining the body's regulatory mechanisms instead of overriding them.
- Clinical data shows different metabolic profiles. RhGH administered at replacement doses (0.3–0.6 mg/day) typically increases fasting glucose and insulin resistance markers within 6–12 weeks due to GH's direct antagonism of insulin signaling in muscle and adipose tissue. Ibutamoren studies found transient increases in fasting glucose (5–8 mg/dL average) but lower rates of clinically significant insulin resistance compared to equivalent IGF-1 elevations from rhGH. Possibly because preserved pulsatility allows tissue sensitivity adaptation.
- Cost and accessibility differ dramatically. Pharmaceutical-grade rhGH ranges from $800–$1,500 per month at therapeutic doses; research-grade ibutamoren costs 85–95% less for protocols generating comparable IGF-1 elevations. The regulatory distinction matters: rhGH is Schedule III in many jurisdictions; ibutamoren remains unscheduled for research purposes in most regions, though athletes should note WADA prohibition for competitive sports.